menu
    • menu
    [{"orgOrder":0,"company":"Institute Of Cardiology & Internal Diseases, Kazakhstan","sponsor":"Merck & Co | Synergy Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"KAZAKHSTAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Elbasvir","moa":"Nonstructural protein 5A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Institute Of Cardiology & Internal Diseases, Kazakhstan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute Of Cardiology & Internal Diseases, Kazakhstan \/ Merck & Co | Synergy Research Group","highestDevelopmentStatusID":"10","companyTruncated":"Institute Of Cardiology & Internal Diseases, Kazakhstan \/ Merck & Co | Synergy Research Group"},{"orgOrder":0,"company":"National Taiwan University Hospital","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Elbasvir","moa":"Nonstructural protein 5A","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"National Taiwan University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Taiwan University Hospital \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"National Taiwan University Hospital \/ Merck & Co"},{"orgOrder":0,"company":"University Hospital, Clermont-Ferrand","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Elbasvir","moa":"Nonstructural protein 5A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University Hospital, Clermont-Ferrand","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Clermont-Ferrand \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"University Hospital, Clermont-Ferrand \/ Merck & Co"},{"orgOrder":0,"company":"King's College Hospital NHS Trust","sponsor":"Merck & Co | Hepatitis C Trust","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Elbasvir","moa":"Nonstructural protein 5A","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"King's College Hospital NHS Trust","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"King's College Hospital NHS Trust \/ Merck & Co | Hepatitis C Trust","highestDevelopmentStatusID":"11","companyTruncated":"King's College Hospital NHS Trust \/ Merck & Co | Hepatitis C Trust"},{"orgOrder":0,"company":"University of California, Los Angeles","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Elbasvir","moa":"Nonstructural protein 5A","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"University of California, Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Los Angeles \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"University of California, Los Angeles \/ Merck & Co"},{"orgOrder":0,"company":"University of Florida","sponsor":"Patient-Centered Outcomes Research Institute | Merck & Co | AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Elbasvir","moa":"Nonstructural protein 5A","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Florida \/ Patient-Centered Outcomes Research Institute | Merck & Co | AbbVie Inc","highestDevelopmentStatusID":"11","companyTruncated":"University of Florida \/ Patient-Centered Outcomes Research Institute | Merck & Co | AbbVie Inc"},{"orgOrder":0,"company":"University of Maryland, Baltimore","sponsor":"Merck & Co | Cairo University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Elbasvir","moa":"Nonstructural protein 5A","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"University of Maryland, Baltimore","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Maryland, Baltimore \/ Merck & Co | Cairo University","highestDevelopmentStatusID":"11","companyTruncated":"University of Maryland, Baltimore \/ Merck & Co | Cairo University"},{"orgOrder":0,"company":"University of Maryland, Baltimore","sponsor":"National Institutes of Health | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Elbasvir","moa":"Nonstructural protein 5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"University of Maryland, Baltimore","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Maryland, Baltimore \/ National Institutes of Health | Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"University of Maryland, Baltimore \/ National Institutes of Health | Merck & Co"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Elbasvir","moa":"Nonstructural protein 5A","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Pennsylvania \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"University of Pennsylvania \/ Merck & Co"},{"orgOrder":0,"company":"Dallas VA Medical Center","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Elbasvir","moa":"Nonstructural protein 5A","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Dallas VA Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dallas VA Medical Center \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Dallas VA Medical Center \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Elbasvir","moa":"Nonstructural protein 5A","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Granules","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Elbasvir","moa":"Nonstructural protein 5A","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Granules","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Elbasvir","moa":"Nonstructural protein 5A","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Elbasvir","moa":"Nonstructural protein 5A","graph1":"Nephrology","graph2":"Phase IV","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Massachusetts General Hospital \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Elbasvir","moa":"Nonstructural protein 5A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Celerion"},{"orgOrder":0,"company":"Bayside Health","sponsor":"Merck & Co | Austin Hospital, Melbourne Australia","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Elbasvir","moa":"Nonstructural protein 5A","graph1":"Oncology","graph2":"Phase III","graph3":"Bayside Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayside Health \/ Merck & Co | Austin Hospital, Melbourne Australia","highestDevelopmentStatusID":"10","companyTruncated":"Bayside Health \/ Merck & Co | Austin Hospital, Melbourne Australia"},{"orgOrder":0,"company":"Norte Study Group","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Elbasvir","moa":"Nonstructural protein 5A","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Norte Study Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Norte Study Group \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Norte Study Group \/ Merck & Co"}]

    Find Clinical Drug Pipeline Developments & Deals for Elbasvir

    Menu

    Elbasvir

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bayside Health

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Bayside Health

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elbasvir

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Merck & Co | Austin Hospital, Melbourne Australia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HepATocellular Cancer Hcv Therapy Study

                            Details : Elbasvir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Hepatocellular.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 14, 2020

                            Lead Product(s) : Elbasvir

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Merck & Co | Austin Hospital, Melbourne Australia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            University of Maryland, Baltimore

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            University of Maryland, Baltimore

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elbasvir

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : National Institutes of Health | Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication

                            Details : Elbasvir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cardiovascular Diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 31, 2019

                            Lead Product(s) : Elbasvir

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : National Institutes of Health | Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            King's College Hospital NHS Trust

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            King's College Hospital NHS Trust

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elbasvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Merck & Co | Hepatitis C Trust

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ATTIC - Access To Treat in the Community

                            Details : Elbasvir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hepatitis C, Chronic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 08, 2019

                            Lead Product(s) : Elbasvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Merck & Co | Hepatitis C Trust

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            University of California, Los Angeles

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            University of California, Los Angeles

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elbasvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk

                            Details : Elbasvir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hepatitis C.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 12, 2018

                            Lead Product(s) : Elbasvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            National Taiwan University Hospital

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            National Taiwan University Hospital

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elbasvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EBR/GZR for HCV-1b Patients Receiving Hemodialysis

                            Details : Elbasvir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hepatitis C.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 05, 2018

                            Lead Product(s) : Elbasvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            University of Maryland, Baltimore

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            University of Maryland, Baltimore

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elbasvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Merck & Co | Cairo University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal D...

                            Details : Elbasvir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hepatitis C.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 22, 2017

                            Lead Product(s) : Elbasvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Merck & Co | Cairo University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Merck & Co

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Merck & Co

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elbasvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)

                            Details : Elbasvir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hepatitis C.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 20, 2017

                            Lead Product(s) : Elbasvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            University of Pennsylvania

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            University of Pennsylvania

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elbasvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C

                            Details : Elbasvir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hepatitis C.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 07, 2017

                            Lead Product(s) : Elbasvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Institute Of Cardiology & Internal Diseases, Kazakhstan

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Institute Of Cardiology & Internal Diseases, Kazakhstan

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elbasvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Merck & Co | Synergy Research Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Open-Label Efficacy and Safety Study of the Elbasvir/ Grazoprevir Fixed Dose Combination Patients With Chronic...

                            Details : Elbasvir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hepatitis C, Chronic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 19, 2017

                            Lead Product(s) : Elbasvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Merck & Co | Synergy Research Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Dallas VA Medical Center

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Dallas VA Medical Center

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Elbasvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Impact of Hepatitis C Therapy and Bone Health

                            Details : Elbasvir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of HIV Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 18, 2017

                            Lead Product(s) : Elbasvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth